Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

605.80 +9.06 (+1.52%)
Streaming Delayed Price Updated: 10:30 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Argenx Se ADR

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
From argenx SE
Via GlobeNewswire
Immunovant Could Potentially Be An M&A Target, Writes Analyst
Via Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
From argenx SE
Via GlobeNewswire
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
From argenx SE
Via GlobeNewswire
Analyst Ratings for argenx
Via Benzinga
Analyst Ratings for argenx
Via Benzinga
Expert Ratings for argenx
Via Benzinga
AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday
Keybanc boosted Five Below, Inc. (NASDAQ: FIVE) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock. Five Below shares fell 1.6% to $183.92 in... 
Via Benzinga
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
From argenx SE
Via GlobeNewswire
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday
Stifel raised argenx SE (NASDAQ: ARGX) price target from $471 to $478. Stifel analyst Alex Thompson maintained a Buy rating on the stock. argenx shares rose 1.1% to $387.07 in pre-market trading. 
Via Benzinga
7 Analysts Have This to Say About argenx
argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
argenx Appoints Ana Cespedes to Board of Directors
From argenx SE
Via GlobeNewswire
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
From argenx SE
Via GlobeNewswire
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
Via Benzinga
argenx Enters Into Agreement To Acquire Priority Review Voucher
From argenx SE
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review
Via Benzinga
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
From argenx SE
Via GlobeNewswire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
McDonald's To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday
Wedbush raised McDonald's Corporation (NYSE: MCD) price target from $265 to $300. Wedbush analyst Nick Setyan maintained the stock with an Outperform rating. McDonald's shares rose 3.3% to close at... 
Via Benzinga
Recap: argenx Q3 Earnings
argenx (NASDAQ:ARGX) reported its Q3 earnings results on Thursday, October 27, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings argenx missed estimated earnings by... 
Via Benzinga
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
From argenx SE
Via GlobeNewswire
Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say
Via Benzinga
Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
Upgrades 
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Argenx Gets European Marketing Authorization For Neuromuscular Disorder Candidate
The European Commission (EC) has granted marketing authorization for Argenx’s (NASDAQ: ARGX) lead asset VYVGART (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.